MCID: NRF003
MIFTS: 42

Neurofibrosarcoma

Categories: Cancer diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Neurofibrosarcoma

MalaCards integrated aliases for Neurofibrosarcoma:

Name: Neurofibrosarcoma 12 77 54 56 6 45 15 74
Malignant Peripheral Nerve Sheath Tumor 74
Neurosarcoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3512
MeSH 45 D018319
SNOMED-CT 69 19897006

Summaries for Neurofibrosarcoma

MalaCards based summary : Neurofibrosarcoma, also known as malignant peripheral nerve sheath tumor, is related to malignant peripheral nerve sheath tumor and neurofibroma. An important gene associated with Neurofibrosarcoma is MXI1 (MAX Interactor 1, Dimerization Protein), and among its related pathways/superpathways is Glioblastoma Multiforme. The drugs Mechlorethamine and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include bone, kidney and testes, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 77 A malignant peripheral nerve sheath tumor (MPNST) is a form of cancer of the connective tissue... more...

Related Diseases for Neurofibrosarcoma

Diseases related to Neurofibrosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Related Disease Score Top Affiliating Genes
1 malignant peripheral nerve sheath tumor 32.4 NF1 NF2
2 neurofibroma 30.6 NF1 NF2
3 neurofibromatosis, type iv, of riccardi 30.2 NF1 NF2
4 plexiform neurofibroma 30.1 NF1 NF2
5 childhood malignant schwannoma 11.1
6 adult malignant schwannoma 11.1
7 neurofibromatosis, type i 10.2
8 sarcoma 10.2
9 tièche-jadassohn nevus 10.2
10 neurofibromatosis, familial spinal 10.2 NF1 NF2
11 plexiform schwannoma 10.2 NF1 NF2
12 immature cataract 10.2 NF1 NF2
13 atypical neurofibroma 10.2 NF1 NF2
14 trigeminal nerve neoplasm 10.1 NF1 NF2
15 neurilemmoma 10.1 NF1 NF2
16 neurilemmoma of the fifth cranial nerve 10.1 NF1 NF2
17 amyloid tumor 10.1 NF1 NF2
18 spinal meningioma 10.1 NF1 NF2
19 spinal canal and spinal cord meningioma 10.1 NF1 NF2
20 neurilemmomatosis 10.1 NF1 NF2
21 optic nerve neoplasm 10.1 NF1 NF2
22 acoustic neuroma 10.1 NF1 NF2
23 cellular schwannoma 10.1 NF1 NF2
24 neurofibromatosis, type ii 10.1 NF1 NF2
25 elephantiasis 10.1 INSRR NF1
26 hypoglycemia 10.1
27 peripheral nervous system neoplasm 10.1 NF1 NF2
28 central nervous system cancer 10.0 NF1 NF2
29 nervous system cancer 10.0 NF1 NF2
30 spondyloarthropathy 1 9.9
31 ovarian cancer 9.9
32 pheochromocytoma 9.9
33 lymphoma, hodgkin, classic 9.9
34 myasthenia gravis 9.9
35 thymoma, familial 9.9
36 wilms tumor 5 9.9
37 wilms tumor 6 9.9
38 angiosarcoma 9.9
39 lymphoma 9.9
40 graves' disease 9.9
41 hyperinsulinemic hypoglycemia 9.9
42 leiomyosarcoma 9.9
43 neuroma 9.9
44 thymoma 9.9
45 femoral neuropathy 9.9
46 spondylitis 9.9
47 neuropathy 9.9
48 myasthenia gravis congenital 9.9
49 opsoclonus-myoclonus syndrome 9.9
50 myoclonus 9.9

Graphical network of the top 20 diseases related to Neurofibrosarcoma:



Diseases related to Neurofibrosarcoma

Symptoms & Phenotypes for Neurofibrosarcoma

GenomeRNAi Phenotypes related to Neurofibrosarcoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00107-A-1 9.44 DCK
2 Decreased viability GR00221-A-1 9.44 DCK INSRR NF1
3 Decreased viability GR00221-A-2 9.44 DCK NF1
4 Decreased viability GR00221-A-4 9.44 DCK NF1
5 Decreased viability GR00240-S-1 9.44 DCK
6 Decreased viability GR00301-A 9.44 INSRR
7 Decreased viability GR00402-S-2 9.44 DCK INSRR NF1

MGI Mouse Phenotypes related to Neurofibrosarcoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.55 DCK MXI1 NF1 NF2 TP73
2 neoplasm MP:0002006 9.26 MXI1 NF1 NF2 TP73
3 renal/urinary system MP:0005367 8.92 INSRR MXI1 NF1 NF2

Drugs & Therapeutics for Neurofibrosarcoma

Drugs for Neurofibrosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 107)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 51-75-2 4033
2
Ifosfamide Approved Phase 3,Phase 2,Phase 1,Not Applicable 3778-73-2 3690
3
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
4
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
5
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
6
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
7
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
8
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
9
Epirubicin Approved Phase 3 56420-45-2 41867
10
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
11
Trabectedin Approved, Investigational Phase 3,Phase 2 114899-77-3 108150
12
Dacarbazine Approved, Investigational Phase 3,Phase 2 4342-03-4 5351166
13
Docetaxel Approved, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124
14
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
15
Daunorubicin Approved Phase 2, Phase 3 20830-81-3 30323
16
Histamine Approved, Investigational Phase 3 51-45-6 774
17
Cyproheptadine Approved Phase 3 129-03-3 2913
18
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1,Not Applicable 31703
19 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
20 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
21 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
22 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
23 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
24
Isophosphamide mustard Phase 3,Phase 2,Phase 1,Not Applicable 0
25 Immunologic Factors Phase 3,Phase 1,Phase 2
26 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
27 Etoposide phosphate Phase 3,Phase 2
28 Nucleic Acid Synthesis Inhibitors Phase 3
29 Antirheumatic Agents Phase 3,Phase 1
30 Antimitotic Agents Phase 3,Phase 2,Phase 1
31 Anti-Infective Agents Phase 3,Phase 2,Phase 1
32 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
33 Protein Kinase Inhibitors Phase 2, Phase 3,Phase 1
34 Imatinib Mesylate Phase 2, Phase 3,Phase 1 220127-57-1 123596
35 Antiviral Agents Phase 3,Phase 2,Phase 1
36 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
37 Antimetabolites Phase 3,Phase 2,Phase 1
38 Neurotransmitter Agents Phase 3,Phase 1
39 Histamine Antagonists Phase 3
40 Gastrointestinal Agents Phase 3
41 Serotonin Agents Phase 3
42 Serotonin Antagonists Phase 3
43 Anti-Allergic Agents Phase 3
44 Antipruritics Phase 3
45 Dermatologic Agents Phase 3
46 Histamine H1 Antagonists Phase 3
47
Histamine Phosphate Phase 3 51-74-1 65513
48
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
49
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
50
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 46835353 5284616 6436030

Interventional clinical trials:

(show top 50) (show all 78)
# Name Status NCT ID Phase Drugs
1 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
2 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
3 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
4 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Completed NCT00423618 Phase 3
5 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
6 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
7 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
8 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
9 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
10 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
11 Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy Recruiting NCT01710176 Phase 3 epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3);gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8);trabectedin 1.3 mg/m2;high-dose ifosfamide 14 g/m2, given in in 14 days;etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3);gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)
12 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Active, not recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin;Doxorubicin Hydrochloride;Ifosfamide;Pazopanib;Pazopanib Hydrochloride
13 Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors Terminated NCT00427583 Phase 2, Phase 3 imatinib mesylate
14 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
15 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
16 Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma Unknown status NCT01883518 Phase 1, Phase 2
17 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
18 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
19 S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor Completed NCT00068367 Phase 2 erlotinib hydrochloride
20 SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors Completed NCT01661283 Phase 2 everolimus;bevacizumab
21 SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors) Completed NCT02008877 Phase 1, Phase 2 ganetespib;Sirolimus
22 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors Completed NCT00304083 Phase 2 doxorubicin hydrochloride;etoposide;ifosfamide
23 Sorafenib and Dacarbazine in Soft Tissue Sarcoma Completed NCT00837148 Phase 2 Sorafenib and Dacarbazine
24 Trial of Dasatinib in Advanced Sarcomas Completed NCT00464620 Phase 2 Dasatinib
25 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
26 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2 romidepsin
27 Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01653028 Phase 2 Alisertib
28 Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Completed NCT01614795 Phase 2 Temsirolimus
29 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
30 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
31 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
32 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
33 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
34 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
35 Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00041249 Phase 2 brostallicin
36 Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00041236 Phase 2 exatecan mesylate
37 Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
38 Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma Completed NCT00031915 Phase 2 imatinib mesylate
39 Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma Completed NCT00949325 Phase 1, Phase 2 temsirolimus plus liposomal doxorubicin
40 MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1 Completed NCT02096471 Phase 2 PD-0325901
41 PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors Recruiting NCT02584647 Phase 1, Phase 2 PLX3397;Sirolimus
42 A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma Recruiting NCT02601950 Phase 2 Tazemetostat
43 Hypofractionated Radiotherapy With Sequential Chemotherapy in Primary Unresectable or Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall Recruiting NCT03651375 Phase 2 Sequential chemotherapy - 3 courses of AI
44 Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers Recruiting NCT03215511 Phase 1, Phase 2 LOXO-195
45 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
46 Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2 Dexrazoxane;Doxorubicin
47 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2 Gemcitabine Hydrochloride;Pazopanib Hydrochloride
48 APX005M and Doxorubicin in Advanced Sarcoma Recruiting NCT03719430 Phase 2 Doxorubicin;APX005M
49 A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery Active, not recruiting NCT02691026 Phase 2 Pembrolizumab
50 Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma Active, not recruiting NCT02452554 Phase 2

Search NIH Clinical Center for Neurofibrosarcoma

Cochrane evidence based reviews: neurofibrosarcoma

Genetic Tests for Neurofibrosarcoma

Anatomical Context for Neurofibrosarcoma

MalaCards organs/tissues related to Neurofibrosarcoma:

42
Bone, Kidney, Testes, Prostate, Testis, Brain, Spinal Cord

Publications for Neurofibrosarcoma

Articles related to Neurofibrosarcoma:

(show top 50) (show all 712)
# Title Authors Year
1
Malignant peripheral nerve sheath tumor (MPNST) arising from angiosarcoma: a rare case report. ( 30617438 )
2019
2
Malignant peripheral nerve sheath tumor: Transformation in a patient with neurofibromatosis type 2. ( 30408304 )
2019
3
Linear Accelerator-Based Stereotactic Radiosurgery for Cranial Intraparenchymal Metastasis of a Malignant Peripheral Nerve Sheath Tumor: Case Report and Review of the Literature. ( 30529515 )
2019
4
Malignant peripheral nerve sheath tumor of the transverse colon with peritoneal metastasis: a case report. ( 30654838 )
2019
5
Malignant peripheral nerve sheath tumor of the nasal cavity and nasopharynx in a child: A case report. ( 30681599 )
2019
6
Cutaneous Metastasis of Malignant Peripheral Nerve Sheath Tumor Arising From the Pancreas: A Rarity. ( 30720497 )
2019
7
Prognostic significance of mast cell and microvascular densities in malignant peripheral nerve sheath tumor with and without neurofibromatosis type 1. ( 30735009 )
2019
8
Can we differentiate malignant peripheral nerve sheath tumor from benign neurofibroma without invasive sampling. ( 30774551 )
2019
9
Malignant peripheral nerve sheath tumor of the pancreas-A case report. ( 30785006 )
2019
10
Calebin-A induced death of malignant peripheral nerve sheath tumor cells by activation of histone acetyltransferase. ( 30831486 )
2019
11
Multidisciplinary Approach to Malignant Peripheral Nerve Sheath Tumor of the Trigeminal Nerve: 2-Dimensional Operative Video. ( 30851047 )
2019
12
Immunohistochemical assessment of cyclin D1 and p53 is associated with survival in childhood malignant peripheral nerve sheath tumor. ( 30883338 )
2019
13
Malignant Peripheral Nerve Sheath Tumor With Bilateral Adrenal Metastases: Role of 18F-FDG PET/CT in Response Assessment to Tyrosine Kinase Inhibitor and Liposomal Doxorubicin. ( 30889004 )
2019
14
Malignant Peripheral Nerve Sheath Tumor: Treat or Not Treat? ( 30937055 )
2019
15
Primary cardiac malignant peripheral nerve sheath tumor: a case report. ( 31041634 )
2019
16
NTRK-1 fusion in endocervical fibroblastic malignant peripheral nerve sheath tumor marking eligibility for larotrectinib therapy: A case report. ( 31080864 )
2019
17
Central nervous system metastasis of an intradural malignant peripheral nerve sheath tumor in a dog. ( 31086766 )
2019
18
Nomograms for predicting the overall and cause-specific survival in patients with malignant peripheral nerve sheath tumor: a population-based study. ( 31089923 )
2019
19
Editor's Note: Genomic and Molecular Characterization of Malignant Peripheral Nerve Sheath Tumor Identifies the IGF1R Pathway as a Primary Target for Treatment. ( 31092619 )
2019
20
Primary malignant peripheral nerve sheath tumor of the breast. ( 31111643 )
2019
21
Case Report: Metastasis of a Trigeminal Malignant Peripheral Nerve Sheath Tumor to the Corpus Callosum. ( 29518229 )
2019
22
BCAT1 and miR-2504: novel methylome signature distinguishes spindle/desmoplastic melanoma from superficial malignant peripheral nerve sheath tumor. ( 30310175 )
2019
23
CHD4 as a Potential Biomarker in Differentiating Between Cellular Schwannoma and Malignant Peripheral Nerve Sheath Tumor. ( 28549031 )
2018
24
Clarifying the Distinction Between Malignant Peripheral Nerve Sheath Tumor and Dedifferentiated Liposarcoma: A Critical Reappraisal of the Diagnostic Utility of MDM2 and H3K27me3 Status. ( 29309298 )
2018
25
Correction: Hypoxia-inducible factor 1 alpha is a poor prognostic factor and potential therapeutic target in malignant peripheral nerve sheath tumor. ( 29543881 )
2018
26
A recurrent laryngeal nerve malignant peripheral nerve sheath tumor in a child with neurofibromatosis type 1. ( 30365627 )
2018
27
Malignant Peripheral Nerve Sheath Tumor of the Parotid Gland. ( 30538405 )
2018
28
Novel Treatment of a Malignant Peripheral Nerve Sheath Tumor of the Median Nerve. ( 30656108 )
2018
29
Spinal Intradural Primary Malignant Peripheral Nerve Sheath Tumor with Leptomeningeal Seeding: Case Report and Literature Review. ( 27593814 )
2018
30
Malignant Peripheral Nerve Sheath Tumor in a Patient With BAP1 Tumor Predisposition Syndrome. ( 29061454 )
2018
31
Malignant peripheral nerve sheath tumor: The need to get it right first time around. ( 29115724 )
2018
32
Atypical presentation of a primary cardiac malignant peripheral nerve sheath tumor. ( 29318408 )
2018
33
Tumor expression of survivin, p53, cyclin D1, osteopontin and fibronectin in predicting the response to neo-adjuvant chemotherapy in children with advanced malignant peripheral nerve sheath tumor. ( 29332262 )
2018
34
Targeted next-generation sequencing of malignant peripheral nerve sheath tumor of the pterygopalatine fossa with intracranial metastatic recurrence. ( 29369179 )
2018
35
Malignant Peripheral Nerve Sheath Tumor of the Trigeminal Nerve Involving the Middle and Posterior Cranial Fossa. ( 29408426 )
2018
36
Case of an Intracranial Malignant Peripheral Nerve Sheath Tumor in the Setting of Pacer-dependent Heart Block. ( 29492148 )
2018
37
Retrobulbar malignant peripheral nerve sheath tumor in a golden retriever dog: A challenging diagnosis. ( 29606723 )
2018
38
Intracranial malignant peripheral nerve sheath tumor variant: an unusual neurovascular phenotype sarcoma case invading through the petrous bone. ( 29616298 )
2018
39
Immunohistochemical analysis of epigenetic factors to differentiate malignant peripheral nerve sheath tumor from benign neurofibroma in a patient with mosaic neurofibromatosis type 1: H3 lysine 27 trimethylation stain and enhancer of zeste homolog 2 stain. ( 29687471 )
2018
40
Malignant Peripheral Nerve Sheath Tumor in the Course of the Mandibular Nerve. ( 29883816 )
2018
41
Supraclavicular Brachial Plexus Neurolysis for a Malignant Peripheral Nerve Sheath Tumor: A Case Report. ( 29894352 )
2018
42
Malignant peripheral nerve sheath tumor of the scalp: Two rare case reports. ( 29900032 )
2018
43
Low-Grade Malignant Peripheral Nerve Sheath Tumor Mimicking Schwannoma: Role and Importance of Trimethylated H3K27M Staining. ( 29909207 )
2018
44
Extensive perineural spread of an intrapelvic sciatic malignant peripheral nerve sheath tumor: a case report. ( 29974241 )
2018
45
Melanoma Mimicking Malignant Peripheral Nerve Sheath Tumor with Spread to the Cerebellopontine Angle: Utility of Next-Generation Sequencing in Diagnosis. ( 30050716 )
2018
46
Targeting of AKT/ERK/CTNNB1 by DAW22 as a potential therapeutic compound for malignant peripheral nerve sheath tumor. ( 30112810 )
2018
47
Cutaneous metastases of malignant peripheral nerve sheath tumor: Ineffectiveness of intralesional methotrexate. ( 30128346 )
2018
48
Malignant Peripheral Nerve Sheath Tumor Arising in Schwannomatosis with Multiple Lung Metastases. ( 30144611 )
2018
49
Malignant peripheral nerve sheath tumor originating from the adrenal gland in a dog. ( 30175755 )
2018
50
Malignant peripheral nerve sheath tumor of the thorax: Unusual location of a rare tumor. ( 30197366 )
2018

Variations for Neurofibrosarcoma

ClinVar genetic disease variations for Neurofibrosarcoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 MXI1 NM_130439.3(MXI1): c.362C> T (p.Ala121Val) single nucleotide variant Pathogenic rs137852604 GRCh37 Chromosome 10, 111988034: 111988034
2 MXI1 NM_130439.3(MXI1): c.362C> T (p.Ala121Val) single nucleotide variant Pathogenic rs137852604 GRCh38 Chromosome 10, 110228276: 110228276

Expression for Neurofibrosarcoma

Search GEO for disease gene expression data for Neurofibrosarcoma.

Pathways for Neurofibrosarcoma

Pathways related to Neurofibrosarcoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.67 NF1 NF2

GO Terms for Neurofibrosarcoma

Biological processes related to Neurofibrosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.33 MXI1 NF1 NF2
2 negative regulation of protein kinase activity GO:0006469 9.26 NF1 NF2
3 negative regulation of MAPK cascade GO:0043409 8.96 NF1 NF2
4 negative regulation of cell-matrix adhesion GO:0001953 8.62 NF1 NF2

Sources for Neurofibrosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....